HSA/FSA-eligible products available
Call us
Medical Supplies for Home
#1011215559 | Mfg #1001-0614 | Clinical Laboratory

Rapid Test Kit InteliSwab® Antigen Detection COVID-19 Rapid Test Pro Nasal Swab Sample 25 Tests

TEST, COVID-19 RAPID INTELISWAB PROFESSIONAL KIT (25/BX) D/S
Rapid Test Kit InteliSwab® Antigen Detection COVID-19 Rapid Test Pro Nasal Swab Sample 25 Tests

The InteliSwab COVID-19 Rapid Test Pro is for use under an FDA EUA: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2

Product Specifications

MSFH #
1011215559
Manufacturer #
1001-0614
Brand
United States, Orasure Technologies, InteliSwab®, Rapid Test Kit
Manufacturer
(25) Pouches each containing Test Device
Country of Origin
Absorbent Packet and 0.75 mL Developer Solution Vial
Application
(5) Test Stands, Instructions for Use
Contents 1
Quick Reference Guide
HCPCS
U0002
Number of Tests
25 Tests
Product Dating
MSFH Acceptable Dating: we will ship >= 90 days
Reading Type
Visual Read
Sample Type
Nasal Swab Sample
Test Format
Test Device Format
Test Method
Lateral Flow Immunoassay
Test Name
COVID-19 Rapid Test Pro
Test Type
Antigen Detection
Time to Results
30 to 40 Minute Time to Results
UNSPSC Code
41116205

Description

The InteliSwab™ COVID-19 Rapid Test Pro is a single-use lateral flow immunoassay with an integrated swab, intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal samples from individuals 18 years or older when the sample is self-collected or in individuals 2 years or older when the sample is collected by an adult or healthcare provider

The test is authorized for individuals who are suspected of COVID-19 by their healthcare provider within 7 days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests

This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation

Positive results indicate that viral antigens have been detected, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status; positive results do not exclude bacterial infection or coinfection with other viruses

Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities in accordance with local, state, and federal requirements using appropriate LOINC and SNOMED codes, as defined by the Laboratory In Vitro Diagnostics (LVID) Test Code Mapping for SARS-CoV-2 Tests provided by CDC

Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed; negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions

Negative results should be considered in the context of an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19

The InteliSwab™ COVID-19 Rapid Test Pro is intended for use by medical professionals or trained operators who are proficient in performing tests and trained clinical laboratory personnel or individuals trained in POC settings

Customer Reviews

No reviews yet. Be the first to review this product.

Write a Review

Used to verify your review and never shown to other customers.